Olema Pharmaceuticals experienced a significant decline in its stock price following AstraZeneca's announcement that its Phase 3 SERENA-4 trial did not meet its primary endpoint. This news has raised concerns among investors regarding Olema's lead candidate, palazestrant, which…
Anavex Life Sciences is making strides in its Phase 3 planning for Alzheimer's disease with the FDA, having submitted clinical trial data and reporting a cash position of $118.3 m…
Moderna's shares rose by 2.9% in pre-market trading as they rebounded from a recent decline. This follows a significant rally triggered by positive Phase 3 trial results for its p…
Moderna's stock experienced a significant increase of more than 90% in premarket trading after the company announced positive results from a Phase 3 trial of its personalized mRNA…
A recent Phase 3 trial of the experimental obesity medication retatrutide demonstrated an average weight loss of 25% at the highest dose over 80 weeks, along with improvements in…
BioNTech SE's stock fell by 8% after the company halted its Phase 2 colorectal cancer vaccine trial due to futility. This decision has also affected other mRNA vaccine stocks, inc…